Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 26, No 5 (February 10), 2008: pp. 736-744
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.15.4716

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pritchard, K. I.
Right arrow Articles by Dhesy-Thind, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pritchard, K. I.
Right arrow Articles by Dhesy-Thind, B.
Related Articles
Right arrowRelated Correspondence
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

REVIEW ARTICLE

HER-2 and Topoisomerase II As Predictors of Response to Chemotherapy

Kathleen I. Pritchard, Hans Messersmith, Leela Elavathil, Maureen Trudeau, Frances O’Malley, Bindi Dhesy-Thind

From the Sunnybrook Odette Cancer Centre; Department of Pathology and Laboratory Medicine, Mount Sinai Hospital; Cancer Care; Departments of Medicine and Pathology and Laboratory Medicine, University of Toronto; Ontario, Toronto; McMaster University; Henderson Hospital; and Juravinski Cancer Centre, Hamilton, Ontario, Canada

Corresponding author: Kathleen I. Pritchard, MD, FRCPC, FACP, Sunnybrook Odette Cancer Centre, Department of Medicine, University of Toronto, 2075 Bayview Ave, Toronto, ON M4N 3M5; e-mail: kathy.pritchard{at}sunnybrook.ca

HER2 overexpression or amplification has been shown to be associated with a poor prognostic effect in women with breast cancer. At least eight analyses based on randomized trials have examined the relationship between HER2 and the differential effect of anthracycline compared with non–anthracycline-containing regimens. Only three of these studies were sufficiently powered to show a significant interaction between HER2 and anthracycline- versus non–anthracycline-containing treatments, but because all of the study results tended to be in the same direction, it is not surprising that three recent meta-analyses of published data have suggested that anthracycline-containing regimens provide more benefit than non–anthracycline-containing regimens in women whose tumors are overexpressed or amplified (positive) for HER2. Since topoisomerase II is a known target of the anthracyclines, it has been postulated that this relationship is actually based on the proximity of HER2 to the topoisomerase II{alpha} gene (TOP2A) in the 17q chromosome. At least four recent studies have suggested that deletion and amplification of the TOP2A gene are associated with poor prognosis and are predictive of greater response to anthracycline-containing than to non–anthracycline-containing regimens. However, in at least one of those studies, HER2 positivity was as or more predictive. Although it has been suggested that HER2 positivity is predictive of better response to higher-dose anthracycline-containing regimens compared with standard anthracycline-containing regimens and to taxane- compared with non–taxane-containing regimens, these relationships have not been robust or consistent. Additional studies will be required to clarify these relationships.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Correspondence

  • Hormone Receptor, Grade, Human Epidermal Growth Factor Receptor 2, and Topoisomerase II As Predictors of Response to Chemotherapy
    Rita S. Mehta
    JCO 2008 26: 2596 [Full Text]


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
J. A. Sparano, L. J. Goldstein, B. H. Childs, S. Shak, D. Brassard, S. Badve, F. L. Baehner, R. Bugarini, S. Rowley, E. Perez, et al.
Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer
Clin. Cancer Res., December 15, 2009; 15(24): 7693 - 7700.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. Gianni, L. Norton, N. Wolmark, T. M. Suter, G. Bonadonna, and G. N. Hortobagyi
Role of Anthracyclines in the Treatment of Early Breast Cancer
J. Clin. Oncol., October 1, 2009; 27(28): 4798 - 4808.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
R. Tubbs, W. E. Barlow, G. T. Budd, E. Swain, P. Porter, A. Gown, I-T. Yeh, G. Sledge, C. Shapiro, J. Ingle, et al.
Outcome of Patients With Early-Stage Breast Cancer Treated With Doxorubicin-Based Adjuvant Chemotherapy As a Function of HER2 and TOP2A Status
J. Clin. Oncol., August 20, 2009; 27(24): 3881 - 3886.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
F. J. Esteva and G. N. Hortobagyi
Topoisomerase II{alpha} Amplification and Anthracycline-Based Chemotherapy: The Jury Is Still Out
J. Clin. Oncol., July 20, 2009; 27(21): 3416 - 3417.
[Full Text] [PDF]


Home page
Nucleic Acids ResHome page
M. Stros, E. Polanska, S. Struncova, and S. Pospisilova
HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase II{alpha}
Nucleic Acids Res., April 1, 2009; 37(7): 2070 - 2086.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Jones, F. A. Holmes, J. O'Shaughnessy, J. L. Blum, S. J. Vukelja, K. J. McIntyre, J. E. Pippen, J. H. Bordelon, R. L. Kirby, J. Sandbach, et al.
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735
J. Clin. Oncol., March 10, 2009; 27(8): 1177 - 1183.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. Gianni and P. Valagussa
Anthracyclines and Early Breast Cancer: The End of an Era?
J. Clin. Oncol., March 10, 2009; 27(8): 1155 - 1157.
[Full Text] [PDF]


Home page
JCOHome page
E. de Azambuja, M. Paesmans, M. Beauduin, A. Vindevoghel, N. Cornez, C. Finet, F. Ries, M. T. Closon-Dejardin, J. Kerger, P. Gobert, et al.
Long-Term Benefit of High-Dose Epirubicin in Adjuvant Chemotherapy for Node-Positive Breast Cancer: 15-Year Efficacy Results of the Belgian Multicentre Study
J. Clin. Oncol., February 10, 2009; 27(5): 720 - 725.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Dowsett and A. K. Dunbier
Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer
Clin. Cancer Res., December 15, 2008; 14(24): 8019 - 8026.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
E. Castro and E. de Alava
The risk of taking the part by the whole
Ann. Onc., November 1, 2008; 19(11): 1975 - 1976.
[Full Text] [PDF]


Home page
Ann OncolHome page
S. Menard, A. Balsari, E. Tagliabue, T. Camerini, P. Casalini, R. Bufalino, F. Castiglioni, M. L. Carcangiu, A. Gloghini, S. Scalone, et al.
Biology, prognosis and response to therapy of breast carcinomas according to HER2 score
Ann. Onc., October 1, 2008; 19(10): 1706 - 1712.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
N. C Turner and A. L Jones
Management of breast cancer--Part II
BMJ, July 11, 2008; 337(jul11_2): a540 - a540.
[Full Text]


Home page
JCOHome page
J. Peppercorn and A. H. Partridge
Breast Cancer in Young Women: A New Color or a Different Shade of Pink?
J. Clin. Oncol., July 10, 2008; 26(20): 3303 - 3305.
[Full Text] [PDF]


Home page
JCOHome page
R. S. Mehta
Hormone Receptor, Grade, Human Epidermal Growth Factor Receptor 2, and Topoisomerase II As Predictors of Response to Chemotherapy
J. Clin. Oncol., May 20, 2008; 26(15): 2596 - 2596.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online